NASH - Nonalcoholic Steatohepatitis
Pipeline by Development Stage
Drug Modality Breakdown
Infectious Diseases is an $11.9B market dominated by HIV and hepatitis C treatments in their peak revenue phases, reflecting a mature but stable therapeutic area.
Key Trends
- HIV antiretroviral dominance: Nucleoside Reverse Transcriptase Inhibitors account for 44% of spending
- Patent cliff pressure: $2.8B in revenue from major products facing LOE between 2027–2031
- High trial velocity: 9,337 active trials indicate sustained pipeline development despite market maturity
Career Verdict
Infectious Diseases offers stable, well-compensated roles with strong commercial demand, but limited growth upside—ideal for risk-averse professionals seeking established franchises rather than high-growth opportunities.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | BIKTARVY (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate) | Gilead Sciences | $3.2B | 27% | Peak | Stable | 10.5yr |
| 2 | EPCLUSA (velpatasvir and sofosbuvir) | Gilead Sciences | $877M | 7% | Peak | Stable | 8.2yr |
| 3 | TIVICAY (dolutegravir sodium) | GSK | $657M | 6% | Peak | Declining | 4.1yr |
| 4 | TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) | GSK | $632M | 5% | Peak | Declining | 4.1yr |
| 5 | GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) | Gilead Sciences | $626M | 5% | Peak | Stable | 6.9yr |
Drug Class Breakdown
backbone of HIV treatment, stable demand
hepatitis C treatment, mature market
boosting agents in combination regimens
niche mechanism, limited growth
Career Outlook
StableInfectious Diseases offers predictable career progression and above-average compensation in Commercial roles, supported by 780 current openings and sustained demand from market incumbents. However, patent cliffs affecting $2.8B in near-term revenue (2027–2031) will compress margins and slow hiring after 2028, particularly in Commercial support and field-based roles. The area is best suited for mid-career professionals seeking stability over rapid growth, with limited appeal for early-career scientists pursuing innovation-driven research.
Breaking In
Enter via Commercial or Manufacturing roles at GSK, Sanofi, or Becton Dickinson to build market expertise and commanding salaries ($160K–$237K); avoid pure R&D tracks unless you target specific mechanisms like long-acting injectables.
For Experienced Professionals
Experienced professionals should pursue Market Access, Medical Affairs, or Commercial Leadership roles where patent cliff expertise commands premium compensation; consider consulting or biotech transition if R&D innovation is your priority.
In-Demand Skills
Best For
Hiring Landscape
Infectious Diseases hiring is heavily weighted toward Commercial roles (247 positions, 32% of total), reflecting mature market dynamics focused on market access and brand management. GSK and Becton Dickinson lead hiring (214 and 188 roles), but Gilead Sciences—the market leader by revenue—shows surprisingly low hiring (25 roles), signaling efficiency-driven operations. Salary progression favors Commercial ($275K avg) over R&D ($184K avg), indicating career acceleration through sales and marketing functions.
Top Hiring Companies
By Department
Strong Commercial hiring with premium salaries suggests Infectious Diseases is an excellent landing spot for brand, sales, and market access professionals, but limited R&D hiring indicates reduced innovation investment.
Competitive Landscape
21 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 34 trials with date data
Clinical Trials (34)
Total enrollment: 5,636 patients across 34 trials
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis
Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Phase 2a Study of HPG1860 in Subjects With NASH
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
Study to Evaluate MET642 in Patients With NASH
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations
A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)
A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis
Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.
Multiple Ascending Dose Study of HU6 in High BMI Volunteers
Ascending Dose Study of HU6 in Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients
A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects
Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials
Effect of DMR in the Treatment of NASH
Related Jobs in Infectious Diseases
Vice President, Engineering
Vice President, Engineering
Vice President, Engineering
Vice President, Engineering
Director, Anti-infective Pharmacology
Executive Search Recruiting Coordinator
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.